Study ID,Patient ID,Sample ID,Alpelisib Dose (mg),Alpelisib Scheduling,Breast Cancer Subtype,Cancer Type,Cancer Type Detailed,Clinical Benefit,Endocrine Therapy,Fraction Genome Altered,Measurable Disease,Mutation Count,Off Study Reason,Oncotree Code,Patient Display Name,PIK3CA Pre Treatment Tumor Mutation,PIK3CA Pre Treatment Tumor,Best RECIST Response,Sample Class,Sample Collection Time,Number of Samples Per Patient,Sample Type,Tumor Sequencing Platform,Sex,Somatic Status,TMB (nonsynonymous),Treatment Arm,Treatment Best Response,Weeks on Study
breast_alpelisib_2020,P-0000081,P-0000081-T01-IM3,250,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Not evaluable for response,Letrozole,0.1811,Not evaluable for response,6,Toxicity,IDC,P045,H1047R,MUT,NA,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,6.654931804,C,Not evaluable for response,3
breast_alpelisib_2020,P-0000129,P-0000129-T01-IM3,250,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,0.3354,Yes,1,POD,IDC,P016,WT,WT,-2.3,Tumor,pre-treatment,3,Primary,MSK-IMPACT,Female,Unmatched,1.109155301,A,Stable Disease,16
breast_alpelisib_2020,P-0000138,P-0000138-T02-IM3,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Letrozole,0.045,Yes,14,POD,IDC,P009,E453K;E542K,MUT,-52,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,15.52817421,A,Partial Response,41
breast_alpelisib_2020,P-0000153,P-0000153-T02-IM3,250,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Not evaluable for response,Letrozole,0.0303,Not evaluable for response,1,POD,ILC,P018,WT,WT,NA,Tumor,pre-treatment,1,Primary,MSK-IMPACT,Female,Unmatched,1.109155301,C,Not evaluable for response,5
breast_alpelisib_2020,P-0000204,P-0000204-T02-IM3,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,0.041,Yes,6,POD,IDC,P033,H1047R,MUT,3.5,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,6.654931804,D,Progression of Disease,8
breast_alpelisib_2020,P-0000216,P-0000216-T02-IM3,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,0.3481,Yes,9,POD,IDC,P026,E545K,MUT,-6,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,9.982397705,C,Progression of Disease,8
breast_alpelisib_2020,P-0000234,P-0000234-T01-IM3,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,0.2295,No,4,POD,IDC,P029,M1043I;E542K,MUT,NA,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,4.436621202,D,Stable Disease,53
breast_alpelisib_2020,P-0000247,P-0000247-T02-IM5,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,0.4226,Yes,20,POD,IDC,P059,E545A,MUT,7.3,Tumor,pre-treatment,4,Metastasis,MSK-IMPACT,Female,Unmatched,19.57439395,D-Exp,Stable Disease,8
breast_alpelisib_2020,P-0000414,P-0000414-T01-IM3,250,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Letrozole,0.1259,No,2,Withdrew Consent,IDC,P013,E545K,MUT,NA,Tumor,pre-treatment,1,Primary,MSK-IMPACT,Female,Unmatched,2.218310601,A,Stable Disease,169
breast_alpelisib_2020,P-0000422,P-0000422-T02-IM3,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,0.376,Yes,7,POD,IDC,P032,H1047L,MUT,34.8,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,7.764087104,D,Progression of Disease,8
breast_alpelisib_2020,P-0000514,P-0000514-T02-IM5,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Yes,Exemestane,0.124,No,3,Withdrew Consent,ILC,P052,H1047R,MUT,NA,Tumor,pre-treatment,2,Metastasis,MSK-IMPACT,Female,Unmatched,1.957439395,D-Exp,Stable Disease,143
breast_alpelisib_2020,P-0000624,P-0000624-T01-IM3,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Letrozole,0.2605,Yes,5,POD,IDC,P035,H1047R,MUT,-2,Tumor,pre-treatment,3,Primary,MSK-IMPACT,Female,Unmatched,5.545776503,C,Stable Disease,20
breast_alpelisib_2020,P-0000690,P-0000690-T03-IM5,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,0.1498,No,3,POD,IDC,P034,E542K,MUT,NA,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,2.936159093,D,Stable Disease,29
breast_alpelisib_2020,P-0000786,P-0000786-T01-IM3,250,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,0.4029,Yes,6,POD,IDC,P023,H1047R,MUT,-8.7,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,6.654931804,C,Stable Disease,16
breast_alpelisib_2020,P-0001114,P-0001114-T03-IM5,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,0.0496,Yes,2,POD,IDC,P049,E978Q;E453Q;E545K,MUT,0,Tumor,pre-treatment,2,Metastasis,MSK-IMPACT,Female,Unmatched,1.957439395,D-Exp,Progression of Disease,6
breast_alpelisib_2020,P-0001351,P-0001351-T02-IM5,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,No,Exemestane,0.0125,No,8,POD,ILC,P054,E726K;E545K,MUT,NA,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,7.829757581,D-Exp,Stable Disease,10
breast_alpelisib_2020,P-0001396,P-0001396-T01-IM3,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,0.4003,Yes,4,POD,IDC,P042,H1047R,MUT,-100,Tumor,pre-treatment,5,Metastasis,MSK-IMPACT,Female,Unmatched,4.436621202,D,Complete Response,150
breast_alpelisib_2020,P-0001516,P-0001516-T01-IM3,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,0.0371,Yes,5,POD,IDC,P031,Q546P,MUT,51,Tumor,pre-treatment,4,Metastasis,MSK-IMPACT,Female,Unmatched,5.545776503,C,Progression of Disease,8
breast_alpelisib_2020,P-0001631,P-0001631-T02-IM5,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,0.2875,Yes,5,POD,IDC,P044,M1043L;E545K,MUT,-74.6,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,4.893598488,D,Partial Response,146
breast_alpelisib_2020,P-0001952,P-0001952-T01-IM3,250,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,0.315,Yes,6,POD,IDC,P021,E545K,MUT,0,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,6.654931804,D,Stable Disease,20
breast_alpelisib_2020,P-0001990,P-0001990-T01-IM3,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,0.2504,No,5,POD,IDC,P047,N345K;H1047Y,MUT,NA,Tumor,pre-treatment,5,Metastasis,MSK-IMPACT,Female,Unmatched,5.545776503,D,Progression of Disease,8
breast_alpelisib_2020,P-0002232,P-0002232-T01-IM3,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Not evaluable for response,Exemestane,0.3006,Not evaluable for response,6,Toxicity,IDC,P030,N345K,MUT,NA,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,6.654931804,D,Not evaluable for response,3
breast_alpelisib_2020,P-0002591,P-0002591-T01-IM3,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Yes,Letrozole,0.3549,Yes,4,POD,ILC,P038,H1047R,MUT,-10.3,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,4.436621202,C,Stable Disease,28
breast_alpelisib_2020,P-0002756,P-0002756-T02-IM5,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,0.314,Yes,4,POD,IDC,P046,E453Q;E545K,MUT,-33.8,Tumor,pre-treatment,3,Primary,MSK-IMPACT,Female,Unmatched,3.91487879,D,Partial Response,48
breast_alpelisib_2020,P-0003179,P-0003179-T02-IM5,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,0.0816,Yes,8,POD,IDC,P050,E542K,MUT,-14.8,Tumor,pre-treatment,3,Primary,MSK-IMPACT,Female,Unmatched,7.829757581,D-Exp,Stable Disease,14
breast_alpelisib_2020,P-0003866,P-0003866-T02-IM5,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,0.2378,Yes,2,POD,IDC,P051,E545K,MUT,-47.2,Tumor,pre-treatment,1,Metastasis,MSK-IMPACT,Female,Unmatched,1.957439395,D-Exp,Partial Response,64
breast_alpelisib_2020,P-0003922,P-0003922-T01-IM3,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,0.0211,Yes,NA,POD,IDC,P006,WT,WT,61,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,0,B,Progression of Disease,7
breast_alpelisib_2020,P-0004187,P-0004187-T01-IM5,250,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,0.2506,No,5,POD,IDC,P022,E970K;H1047R,MUT,NA,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,4.893598488,D,Stable Disease,53
breast_alpelisib_2020,P-0004314,P-0004314-T01-IM5,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,0.5762,Yes,7,Toxicity,IDC,P043,H1047R,MUT,27.3,Tumor,pre-treatment,4,Metastasis,MSK-IMPACT,Female,Unmatched,6.851037883,D,Progression of Disease,7
breast_alpelisib_2020,P-0004668,P-0004668-T01-IM5,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,0.0657,No,3,POD,IDC,P014,WT,WT,NA,Tumor,pre-treatment,1,Primary,MSK-IMPACT,Female,Unmatched,2.936159093,B,Stable Disease,8
breast_alpelisib_2020,P-0004702,P-0004702-T03-IM5,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Yes,Exemestane,0.2479,Yes,4,POD,ILC,P057,Q546R,MUT,-35.6,Tumor,pre-treatment,4,Metastasis,MSK-IMPACT,Female,Unmatched,3.91487879,D-Exp,Partial Response,13
breast_alpelisib_2020,P-0005009,P-0005009-T02-IM5,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,0.1167,Yes,2,POD,IDC,P061,H1047R;E542K,MUT,0,Tumor,pre-treatment,2,Primary,MSK-IMPACT,Female,Unmatched,1.957439395,D-Exp,Stable Disease,54
breast_alpelisib_2020,P-0005131,P-0005131-T01-IM5,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,0.0755,Yes,2,Toxicity,IDC,P036,C420R,MUT,-23.6,Tumor,pre-treatment,2,Metastasis,MSK-IMPACT,Female,Unmatched,1.957439395,D,Stable Disease,32
breast_alpelisib_2020,P-0005666,P-0005666-T01-IM5,250,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Yes,Exemestane,0.2144,No,9,POD,ILC,P025,H1047R,MUT,NA,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,8.808477279,D,Stable Disease,17
breast_alpelisib_2020,P-0006650,P-0006650-T01-IM5,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,0.3905,Yes,6,POD,IDC,P053,E545K,MUT,0,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,5.872318186,D-Exp,Stable Disease,9
breast_alpelisib_2020,P-0006866,P-0006866-T01-IM5,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,0.7181,Yes,5,POD,IDC,P060,E545K,MUT,26.5,Tumor,pre-treatment,3,Metastasis,MSK-IMPACT,Female,Unmatched,4.893598488,D-Exp,Progression of Disease,7
breast_alpelisib_2020,P-0008469,P-0008469-T01-IM5,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Letrozole,0.1575,Yes,4,POD,IDC,P028,E542K,MUT,0,Tumor,pre-treatment,2,Metastasis,MSK-IMPACT,Female,Unmatched,3.91487879,C,Stable Disease,72
breast_alpelisib_2020,P001,P001-01-Pre-Tumor,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,No,NA,Toxicity,IDC,NA,WT,WT,NA,Tumor,pre-treatment,1,NA,Sequenom,Female,Unmatched,0,B,Stable Disease,4
breast_alpelisib_2020,P002,P002-01-Pre-Tumor,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,NA,POD,IDC,NA,E545K,MUT,-30,Tumor,pre-treatment,3,NA,Sequenom,Female,Unmatched,0,B,Stable Disease,13
breast_alpelisib_2020,P002,P002-02-Pre-cfDNA,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,26,POD,IDC,NA,E545K,MUT,-30,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,B,Stable Disease,13
breast_alpelisib_2020,P002,P002-04-Post-cfDNA,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,9,POD,IDC,NA,E545K,MUT,-30,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,B,Stable Disease,13
breast_alpelisib_2020,P003,P003-01-Pre-Tumor,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Not evaluable for response,Letrozole,NA,Not evaluable for response,NA,Toxicity,IDC,NA,WT,WT,NA,Tumor,pre-treatment,1,NA,Sequenom,Female,Unmatched,0,A,Not evaluable for response,4
breast_alpelisib_2020,P004,P004-01-Pre-Tumor,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Yes,Letrozole,NA,No,NA,POD,ILC,NA,E542K,MUT,NA,Tumor,pre-treatment,3,NA,Sequenom,Female,Unmatched,0,A,Stable Disease,116
breast_alpelisib_2020,P004,P004-02-Pre-cfDNA,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Yes,Letrozole,NA,No,1,POD,ILC,NA,E542K,MUT,NA,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,A,Stable Disease,116
breast_alpelisib_2020,P004,P004-04-Post-cfDNA,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Yes,Letrozole,NA,No,3,POD,ILC,NA,E542K,MUT,NA,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,A,Stable Disease,116
breast_alpelisib_2020,P005,P005-01-Pre-Tumor,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Not evaluable for response,Letrozole,NA,Not evaluable for response,NA,Withdrew Consent,ILC,NA,Not Done,Not Done,NA,Tumor,pre-treatment,1,NA,Failed,Female,Unmatched,0,A,Not evaluable for response,2
breast_alpelisib_2020,P-0003922,P006-02-Pre-cfDNA,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,1,POD,IDC,P006,WT,WT,61,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,B,Progression of Disease,7
breast_alpelisib_2020,P-0003922,P006-04-Post-cfDNA,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,2,POD,IDC,P006,WT,WT,61,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,B,Progression of Disease,7
breast_alpelisib_2020,SC-her2-073-M,P007-02-Pre-cfDNA,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,Yes,1,POD,IDC,P007,H1047R,MUT,-19.2,cfDNA,pre-treatment,4,NA,GUARDANT,Female,Matched,NA,B,Stable Disease,29
breast_alpelisib_2020,SC-her2-073-M,P007-03-On-cfDNA,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,Yes,1,POD,IDC,P007,H1047R,MUT,-19.2,cfDNA,on-treatment,4,NA,GUARDANT,Female,Matched,NA,B,Stable Disease,29
breast_alpelisib_2020,SC-her2-073-M,P007-04-Post-cfDNA,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,Yes,2,POD,IDC,P007,H1047R,MUT,-19.2,cfDNA,post-treatment,4,NA,GUARDANT,Female,Matched,NA,B,Stable Disease,29
breast_alpelisib_2020,P008,P008-01-Pre-Tumor,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,1,POD,IDC,NA,H1047R,MUT,65,Tumor,pre-treatment,4,NA,Foundation,Female,Unmatched,1.713329187,B,Progression of Disease,9
breast_alpelisib_2020,P008,P008-02-Pre1-cfDNA,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,2,POD,IDC,NA,H1047R,MUT,65,cfDNA,pre-treatment,4,NA,GUARDANT,Female,Matched,NA,B,Progression of Disease,9
breast_alpelisib_2020,P008,P008-02-Pre2-cfDNA,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,1,POD,IDC,NA,H1047R,MUT,65,cfDNA,pre-treatment,4,NA,GUARDANT,Female,Matched,NA,B,Progression of Disease,9
breast_alpelisib_2020,P008,P008-04-Post-cfDNA,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,2,POD,IDC,NA,H1047R,MUT,65,cfDNA,post-treatment,4,NA,GUARDANT,Female,Matched,NA,B,Progression of Disease,9
breast_alpelisib_2020,P-0000138,P009-02-Pre-cfDNA,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Letrozole,NA,Yes,30,POD,IDC,P009,E453K;E542K,MUT,-52,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,A,Partial Response,41
breast_alpelisib_2020,P-0000138,P009-04-Post-cfDNA,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Letrozole,NA,Yes,61,POD,IDC,P009,E453K;E542K,MUT,-52,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,A,Partial Response,41
breast_alpelisib_2020,P012,P012-01-Pre-Tumor,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Not evaluable for response,Exemestane,NA,Not evaluable for response,NA,Toxicity,IDC,NA,E542K,MUT,NA,Tumor,pre-treatment,1,NA,Sequenom,Female,Unmatched,0,B,Not evaluable for response,2
breast_alpelisib_2020,P-0000129,P016-02-Pre-cfDNA,250,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,NA,Yes,2,POD,IDC,P016,WT,WT,-2.3,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,A,Stable Disease,16
breast_alpelisib_2020,P-0000129,P016-04-Post-cfDNA,250,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,NA,Yes,5,POD,IDC,P016,WT,WT,-2.3,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,A,Stable Disease,16
breast_alpelisib_2020,p_SC_adbrca_002,P017-04-Post-cfDNA,250,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Letrozole,NA,Yes,9,POD,IDC,P017,H1047L,MUT,-16.3,cfDNA,post-treatment,2,NA,GUARDANT,Female,Matched,NA,A,Stable Disease,21
breast_alpelisib_2020,P019,P019-01-Pre-Tumor,250,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Not evaluable for response,Letrozole,NA,Not evaluable for response,NA,POD,ILC,NA,E545K,MUT,NA,Tumor,pre-treatment,2,NA,Sequenom,Female,Unmatched,0,C,Not evaluable for response,5
breast_alpelisib_2020,P019,P019-02-Pre-cfDNA,250,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Not evaluable for response,Letrozole,NA,Not evaluable for response,3,POD,ILC,NA,E545K,MUT,NA,cfDNA,pre-treatment,2,NA,GUARDANT,Female,Matched,NA,C,Not evaluable for response,5
breast_alpelisib_2020,P-0001952,P021-02-Pre-cfDNA,250,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,Yes,3,POD,IDC,P021,E545K,MUT,0,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Stable Disease,20
breast_alpelisib_2020,P-0001952,P021-04-Post-cfDNA,250,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,Yes,3,POD,IDC,P021,E545K,MUT,0,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Stable Disease,20
breast_alpelisib_2020,P-0004187,P022-02-Pre-cfDNA,250,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,No,2,POD,IDC,P022,E970K;H1047R,MUT,NA,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Stable Disease,53
breast_alpelisib_2020,P-0004187,P022-04-Post-cfDNA,250,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,No,2,POD,IDC,P022,E970K;H1047R,MUT,NA,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Stable Disease,53
breast_alpelisib_2020,P-0000786,P023-02-Pre-cfDNA,250,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,NA,Yes,4,POD,IDC,P023,H1047R,MUT,-8.7,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,C,Stable Disease,16
breast_alpelisib_2020,P-0000786,P023-04-Post-cfDNA,250,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,NA,Yes,3,POD,IDC,P023,H1047R,MUT,-8.7,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,C,Stable Disease,16
breast_alpelisib_2020,P-0005666,P025-02-Pre-cfDNA,250,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Yes,Exemestane,NA,No,4,POD,ILC,P025,H1047R,MUT,NA,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Stable Disease,17
breast_alpelisib_2020,P-0005666,P025-04-Post-cfDNA,250,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Yes,Exemestane,NA,No,9,POD,ILC,P025,H1047R,MUT,NA,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Stable Disease,17
breast_alpelisib_2020,P-0000216,P026-02-Pre-cfDNA,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,NA,Yes,7,POD,IDC,P026,E545K,MUT,-6,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,C,Progression of Disease,8
breast_alpelisib_2020,P-0000216,P026-04-Post-cfDNA,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,NA,Yes,5,POD,IDC,P026,E545K,MUT,-6,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,C,Progression of Disease,8
breast_alpelisib_2020,P-0008469,P028-04-Post-cfDNA,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Letrozole,NA,Yes,1,POD,IDC,P028,E542K,MUT,0,cfDNA,post-treatment,2,NA,GUARDANT,Female,Matched,NA,C,Stable Disease,72
breast_alpelisib_2020,P-0000234,P029-02-Pre-cfDNA,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,No,4,POD,IDC,P029,M1043I;E542K,MUT,NA,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Stable Disease,53
breast_alpelisib_2020,P-0000234,P029-04-Post-cfDNA,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,No,4,POD,IDC,P029,M1043I;E542K,MUT,NA,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Stable Disease,53
breast_alpelisib_2020,P-0002232,P030-02-Pre-cfDNA,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Not evaluable for response,Exemestane,NA,Not evaluable for response,4,Toxicity,IDC,P030,N345K,MUT,NA,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Not evaluable for response,3
breast_alpelisib_2020,P-0002232,P030-03-On-cfDNA,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Not evaluable for response,Exemestane,NA,Not evaluable for response,3,Toxicity,IDC,P030,N345K,MUT,NA,cfDNA,on-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Not evaluable for response,3
breast_alpelisib_2020,P-0001516,P031-02-Pre-cfDNA,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,NA,Yes,4,POD,IDC,P031,Q546P,MUT,51,cfDNA,pre-treatment,4,NA,GUARDANT,Female,Matched,NA,C,Progression of Disease,8
breast_alpelisib_2020,P-0001516,P031-03-On-cfDNA,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,NA,Yes,3,POD,IDC,P031,Q546P,MUT,51,cfDNA,on-treatment,4,NA,GUARDANT,Female,Matched,NA,C,Progression of Disease,8
breast_alpelisib_2020,P-0001516,P031-04-Post-cfDNA,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,NA,Yes,3,POD,IDC,P031,Q546P,MUT,51,cfDNA,post-treatment,4,NA,GUARDANT,Female,Matched,NA,C,Progression of Disease,8
breast_alpelisib_2020,P-0000422,P032-02-Pre-cfDNA,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,8,POD,IDC,P032,H1047L,MUT,34.8,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Progression of Disease,8
breast_alpelisib_2020,P-0000422,P032-04-Post-cfDNA,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,9,POD,IDC,P032,H1047L,MUT,34.8,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Progression of Disease,8
breast_alpelisib_2020,P-0000204,P033-02-Pre-cfDNA,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,2,POD,IDC,P033,H1047R,MUT,3.5,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Progression of Disease,8
breast_alpelisib_2020,P-0000204,P033-04-Post-cfDNA,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,3,POD,IDC,P033,H1047R,MUT,3.5,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Progression of Disease,8
breast_alpelisib_2020,P-0000690,P034-02-Pre-cfDNA,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,No,2,POD,IDC,P034,E542K,MUT,NA,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Stable Disease,29
breast_alpelisib_2020,P-0000690,P034-04-Post-cfDNA,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,No,1,POD,IDC,P034,E542K,MUT,NA,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Stable Disease,29
breast_alpelisib_2020,P-0000624,P035-02-Pre-cfDNA,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Letrozole,NA,Yes,5,POD,IDC,P035,H1047R,MUT,-2,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,C,Stable Disease,20
breast_alpelisib_2020,P-0000624,P035-04-Post-cfDNA,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Letrozole,NA,Yes,3,POD,IDC,P035,H1047R,MUT,-2,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,C,Stable Disease,20
breast_alpelisib_2020,P-0005131,P036-04-Post-cfDNA,300,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,Yes,2,Toxicity,IDC,P036,C420R,MUT,-23.6,cfDNA,post-treatment,2,NA,GUARDANT,Female,Matched,NA,D,Stable Disease,32
breast_alpelisib_2020,P037,P037-01-Pre-Tumor,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,NA,Yes,5,POD,IDC,NA,E110del,MUT,45.1,Tumor,pre-treatment,4,NA,Foundation,Female,Unmatched,8.566645935,C,Progression of Disease,5
breast_alpelisib_2020,P037,P037-02-Pre1-cfDNA,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,NA,Yes,4,POD,IDC,NA,E110del,MUT,45.1,cfDNA,pre-treatment,4,NA,GUARDANT,Female,Matched,NA,C,Progression of Disease,5
breast_alpelisib_2020,P037,P037-02-Pre2-cfDNA,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,NA,Yes,5,POD,IDC,NA,E110del,MUT,45.1,cfDNA,pre-treatment,4,NA,GUARDANT,Female,Matched,NA,C,Progression of Disease,5
breast_alpelisib_2020,P037,P037-03-On-cfDNA,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Letrozole,NA,Yes,8,POD,IDC,NA,E110del,MUT,45.1,cfDNA,on-treatment,4,NA,GUARDANT,Female,Matched,NA,C,Progression of Disease,5
breast_alpelisib_2020,P-0002591,P038-02-Pre-cfDNA,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Yes,Letrozole,NA,Yes,6,POD,ILC,P038,H1047R,MUT,-10.3,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,C,Stable Disease,28
breast_alpelisib_2020,P-0002591,P038-04-Post-cfDNA,300,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Yes,Letrozole,NA,Yes,7,POD,ILC,P038,H1047R,MUT,-10.3,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,C,Stable Disease,28
breast_alpelisib_2020,P039,P039-01-Pre-Tumor,250,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Letrozole,NA,No,NA,POD,IDC,NA,H1047R,MUT,NA,Tumor,pre-treatment,3,NA,Sequenom,Female,Unmatched,0,C,Stable Disease,49
breast_alpelisib_2020,P039,P039-02-Pre-cfDNA,250,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Letrozole,NA,No,1,POD,IDC,NA,H1047R,MUT,NA,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,C,Stable Disease,49
breast_alpelisib_2020,P039,P039-04-Post-cfDNA,250,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Letrozole,NA,No,5,POD,IDC,NA,H1047R,MUT,NA,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,C,Stable Disease,49
breast_alpelisib_2020,P040,P040-01-Pre-Tumor,250,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,No,Letrozole,NA,Yes,NA,POD,ILC,NA,H1047R,MUT,-13.6,Tumor,pre-treatment,3,NA,Sequenom,Female,Unmatched,0,C,Stable Disease,15
breast_alpelisib_2020,P040,P040-02-Pre-cfDNA,250,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,No,Letrozole,NA,Yes,60,POD,ILC,NA,H1047R,MUT,-13.6,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,C,Stable Disease,15
breast_alpelisib_2020,P040,P040-04-Post-cfDNA,250,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,No,Letrozole,NA,Yes,69,POD,ILC,NA,H1047R,MUT,-13.6,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,C,Stable Disease,15
breast_alpelisib_2020,P-0001396,P042-02-Pre-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,Yes,1,POD,IDC,P042,H1047R,MUT,-100,cfDNA,pre-treatment,5,NA,GUARDANT,Female,Matched,NA,D,Complete Response,150
breast_alpelisib_2020,P-0001396,P042-03-On1-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,Yes,1,POD,IDC,P042,H1047R,MUT,-100,cfDNA,on-treatment,5,NA,GUARDANT,Female,Matched,NA,D,Complete Response,150
breast_alpelisib_2020,P-0001396,P042-03-On2-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,Yes,1,POD,IDC,P042,H1047R,MUT,-100,cfDNA,on-treatment,5,NA,GUARDANT,Female,Matched,NA,D,Complete Response,150
breast_alpelisib_2020,P-0001396,P042-04-Post-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,Yes,1,POD,IDC,P042,H1047R,MUT,-100,cfDNA,post-treatment,5,NA,GUARDANT,Female,Matched,NA,D,Complete Response,150
breast_alpelisib_2020,P-0004314,P043-02-Pre-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,3,Toxicity,IDC,P043,H1047R,MUT,27.3,cfDNA,pre-treatment,4,NA,GUARDANT,Female,Matched,NA,D,Progression of Disease,7
breast_alpelisib_2020,P-0004314,P043-03-On-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,2,Toxicity,IDC,P043,H1047R,MUT,27.3,cfDNA,on-treatment,4,NA,GUARDANT,Female,Matched,NA,D,Progression of Disease,7
breast_alpelisib_2020,P-0004314,P043-04-Post-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,4,Toxicity,IDC,P043,H1047R,MUT,27.3,cfDNA,post-treatment,4,NA,GUARDANT,Female,Matched,NA,D,Progression of Disease,7
breast_alpelisib_2020,P-0001631,P044-02-Pre-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,Yes,2,POD,IDC,P044,M1043L;E545K,MUT,-74.6,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Partial Response,146
breast_alpelisib_2020,P-0001631,P044-03-On-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,Yes,2,POD,IDC,P044,M1043L;E545K,MUT,-74.6,cfDNA,on-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Partial Response,146
breast_alpelisib_2020,P-0000081,P045-02-Pre-cfDNA,250,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Not evaluable for response,Letrozole,NA,Not evaluable for response,1,Toxicity,IDC,P045,H1047R,MUT,NA,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,C,Not evaluable for response,3
breast_alpelisib_2020,P-0000081,P045-04-Post-cfDNA,250,Intermittent (7/7),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Not evaluable for response,Letrozole,NA,Not evaluable for response,1,Toxicity,IDC,P045,H1047R,MUT,NA,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,C,Not evaluable for response,3
breast_alpelisib_2020,P-0002756,P046-02-Pre-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,Yes,5,POD,IDC,P046,E453Q;E545K,MUT,-33.8,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Partial Response,48
breast_alpelisib_2020,P-0002756,P046-04-Post-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,Yes,18,POD,IDC,P046,E453Q;E545K,MUT,-33.8,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Partial Response,48
breast_alpelisib_2020,P-0001990,P047-02-Pre1-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,No,3,POD,IDC,P047,N345K;H1047Y,MUT,NA,cfDNA,pre-treatment,5,NA,GUARDANT,Female,Matched,NA,D,Progression of Disease,8
breast_alpelisib_2020,P-0001990,P047-02-Pre2-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,No,1,POD,IDC,P047,N345K;H1047Y,MUT,NA,cfDNA,pre-treatment,5,NA,GUARDANT,Female,Matched,NA,D,Progression of Disease,8
breast_alpelisib_2020,P-0001990,P047-03-On-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,No,4,POD,IDC,P047,N345K;H1047Y,MUT,NA,cfDNA,on-treatment,5,NA,GUARDANT,Female,Matched,NA,D,Progression of Disease,8
breast_alpelisib_2020,P-0001990,P047-04-Post-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,No,8,POD,IDC,P047,N345K;H1047Y,MUT,NA,cfDNA,post-treatment,5,NA,GUARDANT,Female,Matched,NA,D,Progression of Disease,8
breast_alpelisib_2020,P048,P048-01-Pre-Tumor,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,No,NA,POD,IDC,NA,E542K,MUT,NA,Tumor,pre-treatment,3,NA,Sequenom,Female,Unmatched,0,D,Stable Disease,65
breast_alpelisib_2020,P048,P048-02-Pre-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,No,4,POD,IDC,NA,E542K,MUT,NA,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Stable Disease,65
breast_alpelisib_2020,P048,P048-04-Post-cfDNA,350,Intermittent (5/2),HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,No,3,POD,IDC,NA,E542K,MUT,NA,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,D,Stable Disease,65
breast_alpelisib_2020,P-0001114,P049-04-Post-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,2,POD,IDC,P049,E978Q;E453Q;E545K,MUT,0,cfDNA,post-treatment,2,NA,GUARDANT,Female,Matched,NA,D-Exp,Progression of Disease,6
breast_alpelisib_2020,P-0003179,P050-02-Pre-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,4,POD,IDC,P050,E542K,MUT,-14.8,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,D-Exp,Stable Disease,14
breast_alpelisib_2020,P-0003179,P050-04-Post-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,6,POD,IDC,P050,E542K,MUT,-14.8,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,D-Exp,Stable Disease,14
breast_alpelisib_2020,P-0000514,P052-04-Post-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Yes,Exemestane,NA,No,4,Withdrew Consent,ILC,P052,H1047R,MUT,NA,cfDNA,post-treatment,2,NA,GUARDANT,Female,Matched,NA,D-Exp,Stable Disease,143
breast_alpelisib_2020,P-0006650,P053-02-Pre-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,7,POD,IDC,P053,E545K,MUT,0,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,D-Exp,Stable Disease,9
breast_alpelisib_2020,P-0006650,P053-04-Post-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,5,POD,IDC,P053,E545K,MUT,0,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,D-Exp,Stable Disease,9
breast_alpelisib_2020,P-0001351,P054-02-Pre-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,No,Exemestane,NA,No,4,POD,ILC,P054,E726K;E545K,MUT,NA,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,D-Exp,Stable Disease,10
breast_alpelisib_2020,P-0001351,P054-04-Post-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,No,Exemestane,NA,No,16,POD,ILC,P054,E726K;E545K,MUT,NA,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,D-Exp,Stable Disease,10
breast_alpelisib_2020,P-0004702,P057-02-Pre-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Yes,Exemestane,NA,Yes,3,POD,ILC,P057,Q546R,MUT,-35.6,cfDNA,pre-treatment,4,NA,GUARDANT,Female,Matched,NA,D-Exp,Partial Response,13
breast_alpelisib_2020,P-0004702,P057-03-On-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Yes,Exemestane,NA,Yes,2,POD,ILC,P057,Q546R,MUT,-35.6,cfDNA,on-treatment,4,NA,GUARDANT,Female,Matched,NA,D-Exp,Partial Response,13
breast_alpelisib_2020,P-0004702,P057-04-Post-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Lobular Carcinoma,Yes,Exemestane,NA,Yes,2,POD,ILC,P057,Q546R,MUT,-35.6,cfDNA,post-treatment,4,NA,GUARDANT,Female,Matched,NA,D-Exp,Partial Response,13
breast_alpelisib_2020,P-0000247,P059-02-Pre-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,5,POD,IDC,P059,E545A,MUT,7.3,cfDNA,pre-treatment,4,NA,GUARDANT,Female,Matched,NA,D-Exp,Stable Disease,8
breast_alpelisib_2020,P-0000247,P059-03-On-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,2,POD,IDC,P059,E545A,MUT,7.3,cfDNA,on-treatment,4,NA,GUARDANT,Female,Matched,NA,D-Exp,Stable Disease,8
breast_alpelisib_2020,P-0000247,P059-04-Post-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,6,POD,IDC,P059,E545A,MUT,7.3,cfDNA,post-treatment,4,NA,GUARDANT,Female,Matched,NA,D-Exp,Stable Disease,8
breast_alpelisib_2020,P-0006866,P060-02-Pre-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,6,POD,IDC,P060,E545K,MUT,26.5,cfDNA,pre-treatment,3,NA,GUARDANT,Female,Matched,NA,D-Exp,Progression of Disease,7
breast_alpelisib_2020,P-0006866,P060-04-Post-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,No,Exemestane,NA,Yes,6,POD,IDC,P060,E545K,MUT,26.5,cfDNA,post-treatment,3,NA,GUARDANT,Female,Matched,NA,D-Exp,Progression of Disease,7
breast_alpelisib_2020,P-0005009,P061-04-Post-cfDNA,350,D-Exp,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,NA,Yes,2,POD,IDC,P061,H1047R;E542K,MUT,0,cfDNA,post-treatment,2,NA,GUARDANT,Female,Matched,NA,D-Exp,Stable Disease,54
breast_alpelisib_2020,SC-her2-073-M,SC-her2-073-M,300,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Exemestane,0.5551,Yes,3,POD,IDC,P007,H1047R,MUT,-19.2,Tumor,pre-treatment,4,Metastasis,MSK-IMPACT,Female,Matched,2.936159093,B,Stable Disease,29
breast_alpelisib_2020,p_SC_adbrca_002,s_SC_adbrca_002_T,250,Continious,HR+/HER2-,Breast Cancer,Breast Invasive Ductal Carcinoma,Yes,Letrozole,0.0015,Yes,1,POD,IDC,P017,H1047L,MUT,-16.3,Tumor,pre-treatment,2,NA,MSK-IMPACT,Female,Matched,1.109155301,A,Stable Disease,21